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Background: Tocilizumab is a humanized monoclonal antibody showing high-affinity binding to both soluble
interleukin-6 receptor (sIL-6R) and membrane bound IL-6R (mIL-6R), thereby preventing pro-inflammatory effects of
IL-6. However, therapeutic antibodies still have practical limitations. To overcome these limitations, we generated
Tocilizumab specific epitope mimics by using the phage display technology and tested whether the peptide mimics
could induce similar humoral responses in mice immunized with the peptides.
Results: Seven phage mimics were obtained by using phage display peptide library. Four phage mimics
(YHTTDKLFYMMR, YSAYEFEYILSS, KTMSAEEFDNWL and LTSHTYRSQADT) were shown to mimic Tocilizumab
epitope using immunoassays. The mimotopes were conjugated to immunogenic carrier proteins and used to
intraperitoneally immunize BALB/c mice. Sera from the mimotopes immunized mice not only showed specific
binding to recombinant IL-6R, but can also IL-6R expressed in Hela, U-937, Jurkat cell lines and in fibroblast-like
synoviocytes from patients with RA (FLS-RA). Furthermore, sera from mice immunized with mimotopes-KLH conjugate
could reduce the level of phosphorylated- signal transducers and activator of transcription (STAT3), STAT3,
phosphorylated- extracellular signal-regulated kinase (Erk) 1/2 and Erk1/2 in HeLa and Jurkat cells. Antibody-dependent
cellular cytotoxicity (ADCC) assay showed that antibodies induced by mimotopes-KLH conjugate could elicit specific
lysis in Hela and U-937 cells.
Conclusions: From phage display library, we successfully isolated four Tocilizumab mimotopes which induced specific
humoral and cellular reponses in vitro and in vivo.
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Rheumatoid arthritis (RA) is an autoimmune inflammatory
disease characterized by abnormal immune responses
which lead to persistent synovitis and ultimately progres-
sive destruction of cartilage and bone in multiple joints.
Among great progress in underlying the pathogenesis of
RA, overexpression of inflammatory cytokines recruited by
activated synovial fibroblasts is thought to play an import-
ant role in synovial hyperplasia and joint destruction [1].
Interleukin-6 (IL-6), a pleiotropic cytokine, contributes to
the regulation of the immune response, inflammation, and
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unless otherwise stated.been demonstrated to play a crucial role in pathogenesis of
rheumatoid arthritis [3, 4], including promoting leukocyte
recruitment to the site of inflammation [5], helping naive
T cell differentiation to T helper 17 cells [6], stimulating
osteoclast maturation and activation via receptor activator
of nuclear factor-Κb ligand (RANKL) [7], promoting
angiogenesis by increasing production of vascular endothe-
lial growth factor (VEGF) [8]. These findings suggest that
targeting IL-6 can be used as a therapeutic strategy and is
a promising alternative in the treatment of RA.
Tocilizumab is a humanized monoclonal antibody
(mAb) that specifically targets both soluble interleukin-6
receptor (sIL-6R) and membrane bound interleukin-6
receptor (mIL-6R) with a high affinity, thereby prevent-
ing pro-inflammatory effects of IL-6 [9]. To present, the
application of Tocilizumab is licensed for the treatment
of RA [10, 11], systemic juvenile idiopathic arthritis
(sJIA) [12, 13] and Castleman’s disease [14, 15] andhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ever, therapeutic antibodies still have practical limita-
tions. For instance, obstacles in production, high dose in
application lead to a relatively high price and persist
blocking activity needs repeatedly administration.
Active immunization using epitope peptides to initiate
the ongoing production of the desired antibody type
would be an attractive alternative. However, due to im-
mune tolerance, the use of a natural epitope peptide alone
is inefficient in inducing efficient immune response [16].
Mimotopes are small peptides that structurally mimic a
given antibody-binding site but are composed of different
amino acids [17, 18]. Active immunization using mimo-
topes would induce antibodies to recognize the mimicked
epitope. Notably, mimotopes can be isolated from phage
display peptide libraries [19]. In current study, to make a
substitution of Tocilizumab, we screened and identified
four peptides that can mimic the natural epitope of Toci-
lizumab by using the phage display technology.Methods
Cell lines and anti-IL-6R antibody
Human epithelial adenocarcinoma cell line HeLa was
kindly provided by Dr. Han (Center for Human Disease
Genomics, Department of Immunology, College of Basic
Medical Sciences, Peking University). Human histiocytic
lymphoma cell line U-937 and human acute T-cell
leukemia cell line Jurkat were provided by medical re-
search center, Peking University Third Hospital. Hela,
U-937 and Jurkat cells were grown in RPMI 1640
medium (ATCC, Manassas, VA) supplemented with
10 % fetal bovine serum (FBS, HyClone Laboratories,
Logan, UT), 100U/ml penicillin and 100 mg/ml strepto-
mycin. Fibroblast-like synoviocytes from patients with
RA (FLS-RA) were isolated from three RA patients at
the time of joint replacement surgery. Patients were in-
formed consent and the approval was obtained from the
Ethics Committee of Baotou Medical College. FLS-RA
cells were maintained in 10 % FBS, 2 mM L-glutamine,
3 mM NaHCO3, 100U/ml penicillin and 100 mg/ml
streptomycin. FLS-RA cells were used to test from pas-
sage 3 to 8. For signaling pathway detection, cells were
grown at 37°C with medium containing 10 % FBS. Two
days later, the medium was replaced by FBS-free
medium with sera from mimotopes immunized mice
with a dilution 1:100 or Tocilizumab (10 μg/ml, Roche
Co. Ltd, Shanghai, China) at 37°C for 2 h. Then the
cells were incubated with human IL-6 (40 ng/ml, R&D
Systems, Minneapolis, MN) for 15 min at 37°C. Total
cell lysates were prepared and the protein concentra-
tion was determined (BCA Protein Assay Kit; Pierce,
Rockford, IL). The lysates were aliquoted and stored
at −80°C.Biopanning of PH.D-12 phage display library
The Ph.D-12 library was purchased from New England
Bio-Labs Inc. (1.5 × 1013 pfu/ml, complexity = 2.7 × 109
transformants; Beverly, MA, USA). Four rounds of bio-
panning procedures were performed according to the
manufacturer’s instructions. Briefly, a 96-well plate
(MaxiSorp; Thermo Fisher Scientific, Shanghai, China)
was coated with 100 μl Tocilizumab [100 μg/ml in
0.1 M NaHCO3 (pH 8.6)] overnight at 4°C. Wells were
then washed 10 times with TBST buffer (50 mM Tris,
150 mM NaCl, pH 7.5 containing 0.1 % Tween-20),
filled with 300 μl of blocking buffer [0.1 M NaHCO3
pH 8.6, 5 mg/ml bovine serum albumin (BSA)] and in-
cubated for 2 h at 37°C. In the first round of biopanning,
10 μl of the phage (1.5 × 1011 pfu) isolated from the ini-
tial library in 100 μl of TBST was incubated with the
coated Tocilizumab for 1 h at 37°C. After repeated
washing with TBST, the bound phage was eluted with
100 μl of 0.2 M Glycine–HCl (pH 2.2) and neutralized
with 15 μl of 1 M Tris–HCl (pH 9.1). The eluate was
used for amplification and titration in an Escherichia coli
ER2738 culture. The recovered phage was subjected to
three additional rounds of biopanning with Tocilizumab
and isotype control (purified human IgG, R&D Systems,
Minneapolis, MN). The eluate from the fourth round of
screening was titrated, and blue clones were randomly
selected and amplified by infecting ER2738.
DNA sequencing
Single-stranded phage DNA was prepared according to
the Ph.D-12 phage display library manufacturer’s in-
structions and was subsequently sequenced by Invitro-
gen Inc. (Shanghai, China).
Specificity enzyme-linked immunosorbent assay (ELISA)
Ninety-six-well plates (MaxiSorp; Thermo Fisher Scientific,
Shanghai, China) were coated with Tocilizumab, an
isotype-matched control antibody [100 μg/ml in 0.1 M
NaHCO3 (pH 8.6)] and 2 % BSA overnight at 4°C. The
plates were then washed with TBS containing 0.5 %
Tween-20 and subsequently blocked using TBS con-
taining 5 % dry milk. 1 × 109 pfu of amplified phages
after the fourth round in TBS containing 5 % dry milk
were incubated with the coated antibodies. The bound
phage particles were detected with a peroxidase-conjugated
mouse anti-phage M13 monoclonal antibody (Pharmacia,
Peapack, USA). The reaction was then developed with 2, 2-
azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS,
SIGMA, St. Louis, MO) as a substrate. The optical density
at 405 nm was measured using an ELISA reader (Thermo
Fisher Scientific, Shanghai, China). The specificity ELISA
was performed in triplicate.
The same procedure was also used to examine the
binding specificity of the isolated phage to Tocilizumab.
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phages were used.
Phage competitive binding assay
Three sets of independent experiments were performed.
In two sets, ELISA plates were coated with Toci-
lizumab (0.5 μg/ml in 0.1 M NaHCO3, pH 8.6) overnight
at 4°C. The plates were then washed with TBST and
blocked by incubation with TBS containing 5 % dry milk.
About 1.5 × 109 pfu of purified phages in TBS containing
5 % dry milk were input and incubated for 1 h. After
washing, the purified phages were eluted with 0.2 M
Glycine–HCl (pH 2.2) and recombinant IL-6R (rIL-6R)
(1 μg/ml, R&D Systems, Minneapolis, MN). An irrelevant
peptide was used as an additional control. Then we per-
formed the titration. The purified phages were also used
to incubate with rIL-6R (1 μg/ml) for 1 h. Then the bound
phage particles were detected with the peroxidase-
conjugated mouse anti-phage M13 monoclonal antibody.
The reaction was then developed with ABTS as a sub-
strate. Absorbance was read at a wavelength of 405 nm
with an ELISA reader.
In Set three, ELISA plates were coated with rIL-6R
(0.1 μg/ml in 0.1 M NaHCO3, pH 8.6) overnight at 4°C.
After the plates were washed and blocked, about 1.5 ×
1011 to 1.5 × 107 pfu of purified phage and Tocilizumab
were co-incubated for 1 h. Then Tocilizumab was de-
tected with Horseradish peroxidase (HRP)–conjugated
Fc-specific goat ant-human IgG (Abcam, Cambridge,
UK). The reaction was then developed with ABTS as a
substrate. Absorbance was read at a wavelength of
405 nm with an ELISA reader. All assays were per-
formed in triplicates.
Synthesis of vaccine constructs
The peptide 4A124 (YHTTDKLFYMMRGGGS), pep-
tide 4A125 (YSAYEFEYILSSGGGS), peptide 4A126
(KTMSAEEFDNWLGGGS), peptide 4A220 (LTSHTYRS
QADTGGGS) and control peptide (MHSSFISPSALGGGS)
were chemically synthesized (SBS, Beijing, China). Each
peptide was then coupled through its C terminus to an
immunogenic carrier, keyhole limpet hemocyanin (KLH,
SIGMA, St. Louis, MO).
Peptide competitive binding assay
ELISA plates were coated with rIL-6R (0.1 μg/ml in
0.1 M NaHCO3, pH 8.6) overnight at 4°C. After the
plates were washed and blocked, synthesized peptides
(10 μg/ml) and Tocilizumab (1 μg/ml) were co-incubated
for 1 h. Then Tocilizumab was detected with HRP–
conjugated Fc-specific goat ant-human IgG (Abcam,
Cambridge, UK). The reaction was then developed with
ABTS as a substrate. Absorbance was read at a wave-
length of 405 nm with an ELISA reader.Immunization of BALB/c mice
Six groups (n = 8) of BALB/c mice were immunized by
intraperitoneal injection with 100 μg of the 4A124
peptide-KLH, the 4A125 peptide-KLH, the 4A126
peptide-KLH, the 4A220 peptide-KLH, the control
peptide-KLH, or KLH alone, at days 1, 22, 43 and 65.
The complete Freund adjuvant/incomplete Freund adju-
vant (CFA/IFA) (SIGMA, St. Louis, MO) was used as an
adjuvant in all groups. Sera were obtained from the tail
veins at day 0, 8, 29, 50 and 79. Ethical approval for use
of animals in research was obtained from the Ethics
Committee of Baotou Medical College. The animals
were maintained in a pathogen-free facility in the Depart-
ment of Laboratory Animal Science of Peking University
Health Science Center. All procedures involving animals
were performed according to the Research Animal Ad-
ministration Guidelines of China and the Guidelines for
the Care and Use of Laboratory Animals in China.
Titer determination and Western blot assay
Serum antibody titers from the immunized BALB/C
mice against rIL-6R were determined using general
ELISA method. ELISA plates were coated with rIL-6R
(10 μg/ml) overnight at 4°C. After the plates were
washed and blocked, pooled serum were added and incu-
bated for 2 h. Then bound antibodies were then incubated
with HRP–conjugated Fc-specific goat ant-mouse IgG
(Abcam, Cambridge, UK). The reaction was then devel-
oped with ABTS as a substrate. Absorbance was read at a
wavelength of 405 nm with an ELISA reader. For antibody
binding assays, aliquots of HeLa, U-937, Jurkat and FLS-
RA cell lysates containing 50 μg protein were separated
using sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis and then electrophoretically transferred to poly-
acrylamide fluoride (PVDF) membranes. The membranes
were blocked with PBS containing 5 % dry milk for 2 h at
37°C and then incubated with Tocilizumab (10 μg/ml) or
pooled serum with a dilution 1:1,000 for overnight at 4°C.
Bound antibodies were then incubated with IRDye
800CW-conjugated goat anti-human and anti-mouse anti-
body (LiCOR, Lincoln, NE) diluted with 1:10,000 for 1 h
at room temperature. The membranes were scanned by
the infrared imaging system (LiCOR, Lincoln, NE). For
antibody competitive assays, aliquots of HeLa cell lysates
containing 40 μg protein were separated using sodium do-
decyl sulfate-polyacrylamide gel electrophoresis and then
transferred to PVDF membranes. The membranes were
blocked with PBS containing 5 % dry milk for 2 h at 37°C
and then incubated with pooled serum with or without
Tocilizumab overnight at 4°C. Bound antibodies were then
incubated with IRDye 800CW-conjugated anti-mouse
antibody. For signaling pathway detection, aliquots of cell
lysates of treated HeLa, U937 and Jurkat cells containing
20 μg protein were separated using sodium dodecyl
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ferred to PVDF membranes. The membranes were
blocked with PBS containing 5 % BSA for 2 h at 37°C and
then reacted with antibodies against phosphorylated
(Y705)-signal transducers and activator of transcription
(STAT)3, phosphorylated -extracellular signal-regulated
kinase (Erk) 1/2, STATand Erk1/2 (Cell Signaling Technol-
ogy, Beverly, USA). Bound antibodies were then incubated
with IRDye 800CW-conjugated anti-rabbit antibody.Fluorescent immunostaining
HeLa, U-937, Jurkat and FLS-RA cells were plated on
confocal dishes (Nest Biotechnology, Hongkong, China).
The cells were grown overnight at 37°C and 5 % CO2.
After washing with PBS, the cells were fixed with 4 %
paraformaldehyde in PBS for 30 min. The confocal
dishes were then blocked with 10 % goat serum in PBS
for 1 h, followed by incubation with Tocilizumab
(100 μg/ml), or the samples from the fourth immune
sera with a dilution 1:200 and incubated at room
temperature for 1 h. The bound antibodies were de-
tected using fluorescein isothiocyanate (FITC)-conju-
gated goat anti-human IgG, and FITC-conjugated goat
anti-mouse IgG (Abcam, Cambridge, UK) with a dilution
1:100 and DAPI (Roche, Shanghai, China) with a dilu-
tion 1:1000. The cells were observed with a fluorescence
microscope (Olympus, Shanghai, China).Antibody-dependent cellular cytotoxicity (ADCC)
Hela, U937 and Jurkat cells were used as specific target
cells. The pooled immune sera of the mimotope-
immunized mice or the control mice from day 65 were
diluted 1:100 for ADCC assays. Lymphocytes of the
naive BALB/c mice (prepared by mashing the spleen and
thymus) were prepared as effector cells. The effector to
target (E: T) cell ratio was about 100:1. The target cells
were incubated in a 96-well plate overnight, and then
the pooled immune sera were added to the wells with
the effector cells. After co-incubation for 72 h, the su-
pernatants were removed carefully. The reaction was
developed with the Cell Counting Kit-8 (Dojindo,
Shanghai, China) diluted 1:10. The optical density at
490 nm was measured using an ELISA reader (Thermo
Fisher Scientific, Shanghai, China).Statistical analysis
Data analyses were performed using GraphPad Prism 5.0
software. Results are expressed as the mean ± SD. Stat-
istical differences were analyzed using the one-way
ANOVA. P values less than 0.05 were considered
significant.Results
Biopanning and mimotopes characterization
As Tocilizumab is a humanized monoclonal antibody
that recognizes sIL-6R and mIL-6R, it was used as the
target protein to screen peptides that can mimic the epi-
tope. The eluted phage titrations increased with each
round of panning, indicating that the phage particles
might carry epitope mimics. The phage titrations were
1.5 × 105 pfu/ml (first round), 2.7 × 105 pfu/ml (second
round), 6.0 × 105 (third round) and 6.8 × 107 pfu/ml
(fourth round), respectively, suggesting the phage bound-
ing to Tocilizumab was well enriched (Fig. 1A).
ELISA was then performed to decide whether the
amplified phages could be specifically recognized by
Tocilizumab. The results showed the amplified phages
from 4 rounds of screening could be well recognized by
both Tocilizumab and isotype controls, but no signifi-
cant difference was observed (Fig. 1B).
Genomic DNAs from 37 phage clones were selected
and sequenced, and seven different insert sequences
were obtained. Then we performed experiments to ob-
serve whether the seven different peptides displayed
could be specifically recognized by Tocilizumab. When
about 1.5 × 109 pfu of the isolated phages were used, the
four mimotope candidates were specifically recognized
by Tocilizumab but not by the isotype-matched controls
(Fig. 1C). To decide which candidate exhibited better
specificity, we reduced the input from 1.5 × 109 to 1.5 ×
107pfu. Our results demonstrated that the phage clones
4A125 and 4A126 showed a better specificity, as com-
pared to the other two (Fig. 1D).
To demonstrate mimicry between the peptides and the
original antigen, three independent phage competitive
binding assay were then performed. In set one, 0.2 M
Glycine–HCl (pH 2.2), rIL-6R and an irrelevant peptide
were used to compete with the binding of phage particles
to Tocilizumab. The bound phage particles were detected
by titer determination. Recombinant IL-6R could displace
a large amount of bound phage from the Tocilizumab, i.e.,
the phage mimic 4A124 bound to Tocilizumab were dis-
placed, about 5.9 × 106 pfu using 0.2 M Glycine–HCl
(pH 2.2), 9.3 × 105 pfu using rIL-6R, only 1.0 × 104 pfu
using the irrelevant peptide, respectively. The phage
mimic 4A125 bound to Tocilizumab were displaced,
about 7.3 × 106 pfu using 0.2 M Glycine–HCl (pH 2.2),
4.8 × 106 pfu using rIL-6R, only 4.0 × 104 pfu using the
irrelevant peptide, respectively. The phage mimic 4A126
bound to Tocilizumab were displaced, about 1.7 × 107 pfu
using 0.2 M Glycine–HCl (pH 2.2), 1.2 × 107 pfu using
rIL-6R, only 4.0 × 104 using the irrelevant peptide, respect-
ively. The phage mimic 4A220 bound to Tocilizumab
were displaced, about 3.3 × 106 using 0.2 M Glycine–HCl
(pH 2.2), 4.5 × 105 using rIL-6R, only 1.6 × 104 using the
irrelevant peptide, respectively (Fig. 2A).
Fig. 1 Four phage mimics were isolated and specifically recognized by Tocilizumab. Four rounds of biopanning were performed to identify the
phage mimics. a The phage titer increased from 1.5 × 105 pfu/ml (first round) to 2.7 × 105 pfu/ml (second round) to 6.0 × 105 (third round) finally
to 6.8 × 107 pfu/ml (fourth round). b Specificity ELISA was then performed to observe whether the whole fourth amplified phage could be
specifically recognized by the Tocilizumab. The results showed the whole fourth amplified phage could be well recognized by both Tocilizumab
and isotype control. Then 37 phage clones was selected and sequenced, and 7 different insert sequences were observed. Then we performed
experiments to observe whether the seven different peptides displayed could be specifically recognized by the Tocilizumab. The results showed
that four mimotope candidates were specifically recognized by Tocilizumab but not by the isotype-matched control antibody when 109 pfu (c) or
107 pfu (d) of the isolated phage particles were used (mean ± SD, *, P < 0.05; **, P < 0.005)
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decreased significantly after we added rIL-6R to compete
with the binding of phage particles to Tocilizumab. The
binding rate decreased to 53.5 % (4A124), 67.1 %
(4A125), 61.3 % (4A126) and 50.8 % (4A220), respect-
ively. The percentage of binding rate was calculated




where Ab is the background absorbance (both phage
particles and rIL-6R were not added), Ap is the phage
absorbance (phage was added) and Api is the absorbance
of the competitive absorbance (both phage particles andrIL-6R were added). The assay was performed in dupli-
cate (Fig. 2B).
In set three, the phage competitive rate of all phage
mimics increased significantly after we added phage par-
ticles to compete with the binding of Tocilizumab to
rIL-6R. The phage competitive rate of phage mimic
4A124 is 32.10 % (1011), 27.2 % (1010), 24.8 % (109),
16.3 % (108), 15. 9 % (107), respectively. The phage com-
petitive rate of phage mimic 4A125 is 33.30 % (1011),
28.10 % (1010), 25.21 % (109), 21.4 % (108), 15.62 % (107),
respectively. The phage competitive rate of phage mimic
4A126 is 36.10 % (1011), 33.30 % (1010), 32.50 % (109),
26.00 % (108), 28.70 % (107), respectively. The phage
competitive rate of phage mimic 4A220 is 28.10 %
(1011), 18.40 % (1010), 10.10 % (109), 6.8 % (108), 7.9 %
Fig. 2 Isolated phage clones can mimic the original antigen. To demonstrate mimicry between the peptides and the original antigen, three
independently phage competitive binding assay were then performed. a In Set one, rIL-6R could displace a large amount of bound phage from
the Tocilizumab by using titration. b In Set two, the phage binding rate of all phage mimics decreased significantly after we added rIL-6R to compete
with the binding of phage particles to Tocilizumab by using ELISA. c In Set three, the phage competitive rate of all phage mimics increased
significantly after we added phage particles to compete with the binding of Tocilizumab to rIL-6R using ELISA (mean ± SD, *, P < 0.05; **, P < 0.005)
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was calculated using the following formula:
phage conpetitive rate% ¼ Atp−Ab
At−Ab
 100%;
where Ab is the background absorbance (both phage
particles and Tocilizumab were not added), At is the
Tocilizumab absorbance (Tocilizumab was added) and
Atp is the absorbance of the competitive absorbance
(both phage particles and Tocilizumab were added)
(Fig. 2C). The assay was performed in duplicate.
Alignment of the insert sequences expressed by phage
clones were shown in Fig. 3.
Peptide competitive assay showed that the binding rate
of Tocilizumab decreased significantly when we added
peptides to compete the binding of Tocilizumab to rIL-
6R. The binding rate decreased to 71.40 % (4A124),
58.60 % (4A125), 51.10 % (4A126), 9.10 % (4A220) and
95.50 % (CP), respectively. The percentage of binding
rate was calculated using the following formula:
phage binding rate% ¼ Apt−Ab
At−Ab
 100%;
where Ab is the background absorbance (both peptides
and Tocilizumab were not added), At is the Tocilizumab
absorbance (Tocilizumab was added) and Apt is theabsorbance of the competitive absorbance (both peptides
and Tocilizumab were added). The assay was performed
in duplicate (Fig. 4).
Immune responses induced by mimotopes vaccination
From the specificity ELISA and the competitive binding
assay results, the four reactive peptides (4A124, 4A125,
4A126 and 4A220) displayed by phage particles were
chosen for chemical synthesis. The immunogenicity of
the mimotope conjugates was then evaluated by immun-
izing BALB/c mice. Mice immunized with the mimotope
conjugates successfully developed antibodies against rIL-
6R (Fig. 5A) and sIL-6R (55 kDa) and/or mIL-6R
(80 kDa) expressed in Hela, U-937 and Jurkat cells
(Fig. 5B). Antibody competitive assays showed that Toci-
lizumab could compete with antibodies induced by
4A220, 4A125 and 4A126-KLH conjugate for IL-6R.
However, we noticed that more antibodies induced by
4A124-KLH conjugate bound to sIL-6R when incubated
with Tocilizumab (Fig. 5C). Results of fluorescent immu-
nostaining revealed that mimotopes induced mouse anti-
bodies could recognize IL-6R in Hela, U-937 and Jurkat
cell line, as compared to the control groups (Fig. 6).
Signaling pathway analysis
We next addressed the question whether IL-6 pathway
could be down-regulated by adding sera from mice
Fig. 3 Alignment of the insert sequences expressed by phage clones. Phe229, Tyr230, Glu278 and Phe279 from the D3 domain of site I contribute the
majority to form the initial IL-6/IL-6Rα binary complex. We aligned the mimotope sequences and found that phage mimics 4A124, 4A125 and 4A126
bear these key amino acids (4A124: Phe229, Tyr230; 4A125: Glu278, Phe279; 4A126: Glu278, Phe279)
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incubation with sera from mice immunized with 4A125
and 4A126-KLH conjugate could reduce the level of
phosphorylated- STAT3 and phosphorylated-Erk1/2, as
compared to the control group. In Jurkat cells, incuba-
tion with sera from mice immunized with 4A220 andFig. 4 Peptides compete with rIL-6R to Tocilizumab. To demonstrate the
Tocilizumab, peptide competitive binding assay was then performed. ELIS
washed and blocked, synthesized peptides (10 μg/ml) and Tocilizumab (1
HRP–conjugated Fc-specific goat ant-human IgG. The results showed tha
peptides to compete with rIL-6R to Tocilizumab (mean ± SD, *, P < 0.05; *4A126-KLH conjugate could reduce the level of STAT3,
phosphorylated-Erk1/2 and Erk1/2. In U937 cells, incuba-
tion with sera from mice immunized with 4A124, 4a125
and 4A126-KLH conjugate could increase the level of
phosphorylated- STAT3, STAT3 and phosphorylated-
Erk1/2 (Fig. 7).peptides and original antigen can share the same binding site of
A plates were coated with rIL-6R (0.1 μg/ml). After the plates were
μg/ml) were co-incubated. Then Tocilizumab was detected with
t Tocilizumab binding rate decreased significantly after we added
*, P < 0.005; ***, p < 0.001)
Fig. 5 Mimotope-induced antibodies for IL-6R recognition. a Titers of the six mouse groups determined by ELISA (the fourth immune serum, day
79) against rIL-6R. b HeLa, Jurkat and U-937 cell lysates were loaded with 50 μg/per lane. IL-6R expressed in HeLa, Jurkat and U-937 detection
using Tocilizumab (lane 1) and the sera from mice immunized with the 4A220-KLH conjugate (lane 2), the 4A124-KLH conjugate (lane 3), 4A125-
KLH conjugate (lane 4), 4A126-KLH conjugate (lane 5), the control peptide-KLH conjugate (lane 6), or the carrier KLH alone (lane 7). Sera were
diluted with 1:1000. The results showed that the antibodies in the sera of the mice immunized with mimotopes could recognize sIL-6R (55KDA)
and/or mIL-6R (80KDA) expressed in HeLa, Jurkat and U-937 cell line. c For antibody competitive assays, HeLa cell lysates were loaded with
40 μg/per lane. IL-6R expressed in HeLa was detected by using sera from mice immunized with the 4A220-KLH conjugate (lane 1), Tocilizumab+
sera from mice immunized with the 4A220-KLH conjugate (lane 2), sera from mice immunized with the 4A124-KLH conjugate (lane 3), Tocilizumab+
sera from mice immunized with the 4A124-KLH conjugate (lane 2), sera from mice immunized with the 4A125-KLH conjugate (lane 5), Tocilizumab+
sera from mice immunized with the 4A125-KLH conjugate (lane 2), sera from mice immunized with the 4A126-KLH conjugate (lane 7) and Tocilizumab
+ sera from mice immunized with the 4A220-KLH conjugate (lane 8). Sera were diluted with 1:1000. The results showed that antibodies induced by
mimotopes-KLH conjugate could compete with Tocilizumab to IL-6R expressed in HeLa cells, except antibodies induced by 4A124-KLH conjugate
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To assess whether the antibodies induced by the mimo-
topes can exhibit specific lysis of the target cells, we
performed ADCC assay. The percentage of cellular
cytotoxicity was calculated using the following formula:




The results showed that the antibodies induced by
4A220, 4A124, 4A125 and 4A126-KLH conjugate elic-
ited specific lysis of 10.59 %, 16.33 %, 27.80 % and
27.98 % of HeLa cells, while the antibodies induced by
4A220, 4A124, 4A125 and 4A126-KLH conjugateelicited specific lysis of 14.23 %, 0.31 %, 25.01 % and
21.55 % of U937 cells. In Jurkat cells, the antibodies in-
duced by 4A220, 4A124, 4A125 and 4A126 elicited spe-
cific lysis of 3.59 %, 4.51 %, 2.12 % and 5.59 % (Fig. 8).
Antibodies induced by mimotopes binding to IL-6R of
FLS-RA
Then we detected whether the antibodies induced by
mimotopes could bind to the FLS-RA cell lysates. The
results of western bolt (Fig. 9A) and fluorescent immu-
nostaining (Fig. 9B) showed that the antibodies in the
sera of the mice immunized with mimotopes could
recognize sIL-6R (55 kDa) and/or mIL-6R (80 kDa)
expressed in FLS-RA.
Fig. 6 Immunofluorescence staining of IL-6R expressed in Hela, U-937 and Jurkat cell line. Cells were incubated with Tocilizumab and pooled serum
followed by FITC-labeled secondary antibodies where the nuclei were stained with DAPI. Cells were visualized with a fluorescence microscope.
a Tocilizumab, (b) sera from mice immunized with 4A220-KLH, (c) sera from mice immunized with 4A124-KLH, (d) sera from mice immunized
with 4A125-KLH, (e) sera from mice immunized with 4A126-KLH, (f) sera from mice immunized with the control peptide-KLH, (g) sera from
mice immunized with KLH alone
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One way to overcome the serious practical limitations of
the monoclonal antibody approach could be to perform
immunization with peptide mimics (mimotopes) of a
naturally occurring epitope that is recognized by the de-
sired antibody. To isolate mimotopes of Tocilizumab,
which has been considered as a promising agent for
treating RA, the phage display was exploited in this
study. After four rounds of biopanning, we isolated four
peptide mimics that were specifically recognized by
Tocilizumab. IL-6 is the prototypic gp130-cytokine and
binds the gp130 receptor through three conserved epi-
topes (sites I, II, and III), of which site III is unique to
gp130-cytokines. IL-6 must first form a complex with a
nonsignaling α receptor, IL-6Rα (PDB: 1N26_A),
through site I. Phe229, Tyr230, Glu278 and Phe279 from
the D3 domain of site I contribute the majority to form
the initial IL-6/IL-6Rα binary complex [20, 21]. We
aligned the mimotope sequences and found that phage
mimics 4A124, 4A125 and 4A126 bear these key amino
acids (4A124: Phe229, Tyr230; 4A125: Glu278, Phe279;
4A126: Glu278, Phe279), suggesting that not only Toci-
lizumab but also the antibodies induced by these mimo-
topes may prevent IL-6 binding to IL-6Rα through these
key amino acids.
Titer determination was performed to evaluate the im-
munogenicity of the isolated mimotopes. As small pep-
tide molecules are not sufficient enough to stimulate the
immune system and may even induce tolerance, we
coupled the mimotopes to an immunogenic carrier,
KLH. Mice immunized with 4A124, 4A125, 4A126 and
4A220 successfully developed high antibody titers against
KLH as well as the mimotopes. The induced sera also rec-
ognized rIL-6R and IL-6R expressed in Hela, U-937 and
Jurkat cell line. Western blots and immunofluorescencestaining further supported that the antibodies induced by
the four isolated mimotopes can bind to IL-6R. Notably,
we found that more antibodies induced by 4A124 bound
to sIL-6R when incubated with Tocilizumab. We assumed
that the antibodies induced by 4A124 may bind both sIL-
6R and Tocilizumab, so Tocilizumab could act like “bridge”
to help antibodies induced by 4A124 to bind sIL-6R.
In signaling pathway analysis, we found that antibodies
induced by mimotopes play different roles in different
cell line. In HeLa and Jurkat cells, antibodies induced by
mimotopes may act as a neutralizing role, but in U937
cells, they may have an aggressive role. Notably, when
we added IL-6 with sera from untreated or CP mice, the
level of phosphorylated-Erk1/2 increased more than IL-6
alone in HeLa cells. Why the level of phosphorylated-
Erk1/2 phosphorylation increased more when adding IL-6
with sera? We assumed that the most likely explanation
was that some homologous cytokines might overlap hu-
man IL-6 to activate signaling pathway in HeLa cells. In
addition, we found that antibodies induced by 4A220 and
4A126-KLH conjugate and Tocilizumab could reduce the
level of total STAT3, phosphorylated-Erk1/2 and total
Erk1/2 in Jurkat cells. The mechanism how anti-IL-6R
antibodies could reduce the level of total STAT3 and
Erk1/2 in Jurkat cells needs further study.
In ADCC assays, we found that anti-sera of all mimo-
topes could not induce ADCC effect against Jurkat cells.
Because Jurkat cells are apt to form colony, we assumed
that the effector cells could not contact to inner target
cells and show significantly specific lysis to Jurkat cells.
The antibodies induced by all the phage mimics show
a similar capacity of binding the IL-6R expressed in
Hela, U-937, Jurkat and FLS-RA cells. We noticed that
mimotope 4A220 may not bear any key amino acids, but
the antibodies induced by 4A220 still recognized IL-6R
Fig. 7 Signaling pathway analysis with mimotope-induced antibodies. We detected the levels of phosphorylated-STAT3, STAT3, phosphorylated-Erk1/2
and Erk1/2 in HeLa, Jurkat and U937 cells to observe whether IL-6 pathway could be down-regulated by when added sera from mice immunized with
mimotopes. Cells were grown at 37 °C with medium containing 10 % FBS. Two days later, the medium was replaced by FBS-free medium with sera
from mimotopes immunized mice with a dilution 1:100 or Tocilizumab (10 μg/ml) at 37 °C for 2 h. Then the cells were incubated with human IL-6
(40 ng/ml) for 15 min at 37 °C. In HeLa cells (a), incubation with sera from mice immunized with 4A125 and 4A126 could partly reduce the levels of
phosphorylated-STAT3 and phosphorylated-Erk1/2, as compared to the control group. In Jurkat cells (b), incubation with sera from mice immunized
with 4A220 and 4A126-KLH conjugate could reduce the level of STAT3, phosphorylated-Erk1/2 and Erk1/2. In U937 cells (c), incubation with sera from
mice immunized with 4A124, 4a125 and 4A126-KLH conjugate could increase the level of phosphorylated- STAT3, STAT3 and phosphorylated-Erk1/2
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Fig. 8 ADCC against HeLa, U937 and Jurkat cells elicited by mimotope-induced antibodies. To assess whether the antibodies induced by the
mimotope conjugates can exhibit specific lysis of the target cells, we performed the ADCC assay. The fourth pooled immune sera of the
mimotope-immunized mice or the control mice were diluted 1:100 and used in ADCC assays. Lymphocytes of the naive BALB/c mice were
prepared as effector cells. The effector to target (E: T) cell ratio was about 100:1. The results showed that the antibodies induced by 4A124, 4A125
and 4A126-KLH conjugate could elicite specific lysis of HeLa and U937 cells. However, no specific lysis was observed in Jurkat cells (mean ± SD, *,
P < 0.05; **, P < 0.005; ***, p < 0.001)
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4A220 is composed of different amino acids, it may
structurally mimic the Tocilizumab-binding site.
Our study demonstrated that active immunization in-
duced by Tocilizumab mimotopes in vivo can produce the
desired antibody. With active immunization, the main
obstacles of passive immunotherapy, specifically the
comparatively short antibody half-life, may be over-
come. Immunological memory will be induced to pro-
vide ongoing protection for vaccinated individuals.
Meanwhile, the immunogenicity of artificial antibodies
may be solved because the antibodies are produced by
the patients themselves. To further evaluate the feasibility
of mimotopes vaccination approach, the mimotopes ofFig. 9 Western blot and immunofluorescence staining with mimotope-in
synoviocytes lysates from three patients with RA were loaded with 40 μg
1) and the sera from mice immunized with the 4A220-KLH conjugate (lan
4), 4A126-KLH conjugate (lane 5), the control peptide-KLH conjugate (lan
b Represent image of IL-6R recognition in FLS-RA. FLS-RA cells were incu
secondary antibodies where the nuclei were stained with DAPI. (a) sera fr
with 4A124-KLH, (c) sera from mice immunized with 4A125-KLH, (d) sera
mice immunized with the control peptide-KLH, (g) sera from mice immun
sera of the mice immunized with mimotopes could recognize IL-6R expreAM16-1 (mAb against murine IL-6R) should be screened
and used to immunize the collagen-induced arthritis
(CIA) animal models for us to observe whether the mimo-
topes of AM16-1 could raise antibodies against the mur-
ine IL-6R and ameliorate the arthritis in animal models.Conclusions
We successfully isolated four mimotopes of Tocilizumab
and demonstrated that active immunization induced by
these mimotopes can produce the desired antibody
in vivo. Mimotopes identified for IL-6R may represent a
novel alternative for treating RA or other autoimmune
diseases.duced antibodies for IL-6R recognition in FLS-RA. a Fibroblast-like
/per lane. IL-6R expressed in FLS-RA detection using Tocilizumab (lane
e 2), the 4A124-KLH conjugate (lane 3), 4A125-KLH conjugate (lane
e 6), or the carrier KLH alone (lane 7). Sera were diluted with 1:1000.
bated with Tocilizumab and pooled serum followed by FITC-labeled
om mice immunized with 4A220-KLH, (b) sera from mice immunized
from mice immunized with 4A126-KLH, (e) Tocilizumab, (f) sera from
ized with KLH alone. The results showed that the antibodies in the
ssed in FLS-RA
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